Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF Review of TA558) [ID1681]

DRAFT NICE guidance does not recommend nivolumab for adjuvant treatment of melanoma with lymph node involvement or metastatic disease that has been completely resected in adults. The most likely estimates are above what NICE considers a cost-effective use of NHS resources.

National Institute for Health and Care Excellence